- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Centessa Pharmaceuticals PLC ADR (CNTA)
Centessa Pharmaceuticals PLC ADR stock price live, this page displays NASDAQ CNTA stock exchange data. View the CNTA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Centessa Pharmaceuticals PLC ADR real time stock price chart below.
What Is the Centessa Pharmaceuticals PLC ADR Stock Price Today?
The Centessa Pharmaceuticals PLC ADR stock price today is 18.05.
What Is the Stock Symbol for Centessa Pharmaceuticals PLC ADR?
The stock symbol for Centessa Pharmaceuticals PLC ADR is ""CNTA.""
What Stock Exchange Does Centessa Pharmaceuticals PLC ADR Trade On?
Centessa Pharmaceuticals PLC ADR is listed and trades on the NASDAQ stock exchange.
Is Centessa Pharmaceuticals PLC ADR a Good Stock to Buy?
Determining whether Centessa Pharmaceuticals PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CNTA quote. (ISIN: US1523091007)
What Is the Centessa Pharmaceuticals PLC ADR Stock Price Today?
The Centessa Pharmaceuticals PLC ADR stock price today is 18.05.
What Is the Stock Symbol for Centessa Pharmaceuticals PLC ADR?
The stock symbol for Centessa Pharmaceuticals PLC ADR is ""CNTA.""
What Stock Exchange Does Centessa Pharmaceuticals PLC ADR Trade On?
Centessa Pharmaceuticals PLC ADR is listed and trades on the NASDAQ stock exchange.
Is Centessa Pharmaceuticals PLC ADR a Good Stock to Buy?
Determining whether Centessa Pharmaceuticals PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CNTA quote. (ISIN: US1523091007)
Fair Value
An estimate of a Centessa Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.23
18.11
52 wk Range
9.60
19.09
CNTA Scorecard
Full Analysis
4 analysts have revised their earnings downwards for the upcoming period
CNTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Centessa Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.2318.11
52 wk Range
9.6019.09
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CNTA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Centessa Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
31.90
Upside
+76.73%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Centessa Pharmaceuticals PLC ADR Company Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Centessa Pharmaceuticals PLC ADR SWOT Analysis
Narcolepsy Breakthrough | Centessa's ORX750 poised to revolutionize $2B narcolepsy treatment market with potential for superior efficacy and once-daily dosing |
Pipeline Diversity | Beyond narcolepsy, Centessa's SerpinPC shows promise in hemophilia treatment, demonstrating the company's multi-faceted approach to drug development |
Market Momentum | CNTA stock surges 108% YTD, with analysts projecting further 50-100% growth potential pending crucial clinical data expected in late 2024 |
Financial Fortitude | Solid balance sheet with more cash than debt positions Centessa for continued R&D investment, while analyst targets range from $24 to $35 |
Compare CNTA to Peers and Sector
Metrics to compare | CNTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCNTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.5x | −2.1x | −0.5x | |
PEG Ratio | 0.71 | −0.12 | 0.00 | |
Price/Book | 7.0x | 1.7x | 2.6x | |
Price / LTM Sales | 161.3x | 8.1x | 3.3x | |
Upside (Analyst Target) | 74.5% | 290.6% | 40.1% | |
Fair Value Upside | Unlock | 16.3% | 5.1% | Unlock |
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 31.90
(+76.73% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-0.38 / -0.3297
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Centessa Pharmaceuticals Trade On?
Centessa Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Centessa Pharmaceuticals?
The stock symbol for Centessa Pharmaceuticals is "CNTA."
What Is the Centessa Pharmaceuticals Market Cap?
As of today, Centessa Pharmaceuticals market cap is 2.42B.
What Is Centessa Pharmaceuticals's Earnings Per Share (TTM)?
The Centessa Pharmaceuticals EPS (TTM) is -1.79.
When Is the Next Centessa Pharmaceuticals Earnings Date?
Centessa Pharmaceuticals will release its next earnings report on 16 Nov 2025.
From a Technical Analysis Perspective, Is CNTA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Centessa Pharmaceuticals Stock Split?
Centessa Pharmaceuticals has split 0 times.
How Many Employees Does Centessa Pharmaceuticals Have?
Centessa Pharmaceuticals has 98 employees.
What is the current trading status of Centessa Pharmaceuticals (CNTA)?
As of 17 Aug 2025, Centessa Pharmaceuticals (CNTA) is trading at a price of 18.05, with a previous close of 17.64. The stock has fluctuated within a day range of 17.23 to 18.11, while its 52-week range spans from 9.60 to 19.09.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.